FAM110B and pancreatic neoplasm: However, our previous study used WGCNA analysis, combined with a survival analysis curve and the GEPIA database for validation, and discovered that FAM110B was linked to a good survival time for patients with pancreatic cancer (Li et al., 2023), which was consistent with the results of Xi and Zhang (2018).